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Purpose of review 12 
Healthy aging is a public health priority. The maintenance of adequate physical function is recognized 13 
as a key element of healthy aging. In recent years, scientific evidence has increased concerning the 14 
ability of lipids, in particular omega 3 polyunsaturated fatty acids (n-3 PUFAs), to positively 15 
influence muscle and overall physical function in older patients. The article will critically review 16 
observational as well as intervention studies on this topic, and it will elucidate the potential biological 17 
mechanisms underlying the beneficial effects of n-3 PUFA on physical function. 18 
Recent findings 19 
Observational studies and clinical trials performed in healthy older patients and in older patients with 20 
chronic diseases mostly found positive effects of n-3 PUFA on muscle metabolism, muscle strength 21 
and in general physical function. 22 
Summary 23 
Although the use of n-3 PUFA might represent an important intervention to preserve physical 24 
function in older adults, several key questions still need to be answered. Above all, large randomized 25 
controlled trials should be performed to confirm the utility of n-3 PUFA as therapeutic agents to 26 
prevent and treat physical function decline in old age. 27 
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KEY POINTS 30 
- Physical function is a key component of healthy aging. 31 
- n-3 PUFA supplementation has been shown in observational and intervention studies to improve 32 
muscle performance and physical function, mainly in healthy older people. 33 
- Large-scale clinical trials are necessary to confirm that these beneficial effects can be obtained in 34 
the general older population, including patients with multimorbidity and frailty. 35 
INTRODUCTION 36 
Healthy aging is public health priority in our society [1]. The WHO report on aging and health defines 37 
healthy aging as ‘the process of developing and maintaining the functional ability that enables well-38 
being in older age’, acknowledging that the ability to function is the most important aspect of health 39 
in the older population. Function can be viewed as a summary measure of the overall effect of aging-40 
related changes, lifestyle and diseases, in the context of the environment and social support. A great 41 
deal of attention is currently devoted to identify the determinants of healthy aging. Nutrition is 42 
considered one of the principal factors influencing aging-related and age-related diseases. Among 43 
nutrients, the role of proteins has been extensively investigated [2], whereas other substances, for 44 
example lipids, have received less consideration. Lipids are molecules whose biological functions 45 
include energy storage, signaling and acting as structural components of cell membranes. Recently, 46 
a number of studies investigated the potential role of lipids, in particular polyunsaturated fatty acids 47 
(PUFAs), in counteracting physical function impairment, which is often related to the loss of muscle 48 
mass and function with aging, that is sarcopenia, in older patients. In this review, we will critically 49 
examine the scientific literature on this topic and highlight areas that deserve further investigation. 50 
POLYUNSATURATED FATTY ACID AND PHYSICAL FUNCTION: OBSERVATIONAL 51 
STUDIES 52 
PUFA contain more than one double bond. The most important PUFA are omega-3 (n-3) and  53 
omega-6 (n-6) PUFA. The former include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA) 54 
and docosahexaenoic acid (DHA), whereas the latter include linoleic acid and arachidonic acid. ALA 55 
and linoleic acid cannot be synthetized by the human body and therefore are essential nutrients. 56 
Observational studies performed during the last decade suggest a potential role of n-3 PUFAs in the 57 
preservation of muscular and physical function in older adults [3–8,9&–11&]. Dietary intake of 58 
PUFAs in relationship to muscle and physical performance has been investigated in different 59 
populations. In the Hertfordshire study, Robinson et al. [3] estimated the average consumption of 60 
foods and assessed muscle function. In both sexes, the most important food positively associated with 61 
grip strength was fatty fish. In Japanese communitydwelling patients of 85 years of age a lower 62 
habitual intake of EPA and DHA was associated with poor functional mobility in men but not in 63 
women [7]. The higher proportion and severity of patients with cognitive impairment among women 64 
could explain this sex difference [7]. At variance, Rousseau et al. [5] found an association between 65 
self-reported dietary intake of n-3 PUFA and physical performance, which was not confirmed in the 66 
multivariable analysis. Another approach to examine the role of PUFA is to measure their levels in 67 
plasma [4,6,8,9&– 11&]. Plasma FAs are good markers of dietary intake. These studies found a 68 
positive correlation between circulatory levels of n-3 PUFA and physical capacity measured as 69 
walking speed [4] and muscle strength [4,10&] in older adults. In the InCHIANTI study, older 70 
patients with impaired lower extremity performance, defined as a short physical performance battery 71 
score less than 9, had lower plasma levels of total PUFA, n-3 and n-6 FAs. Moreover, participants 72 
who experienced a decline in physical performance during the follow-up had lower baseline levels of 73 
n-3 PUFA and higher n-6/n-3 ratio [4]. Similarly, in a population-based sample of French older 74 
adults, a higher percentage of long chain n-3 levels was associated with a lower probability to have 75 
reduced gait speed, whereas a higher ratio between arachidonic acid and n-3 PUFA in plasma was 76 
positively related to lower walking speed [9&]. Finally, n-3 PUFAs were associated with larger 77 
muscle size and greater knee extensor strength [11&] and prospectively with lower risk of mobility 78 
disability in women but not in men in a cohort study in Iceland [10&]. No association was observed 79 
between plasma n-3 PUFAs or n-6 PUFAs and decline in gait speed [10&]. The levels of long chain 80 
n-3 PUFA were significantly lower in cancer patients with sarcopenia [6]. The majority of 81 
observational studies found a relationship between long chain n-3 FAs and physical function, 82 
although some negative results have been reported and the association was not consistently found in 83 
both sexes. The relationship has been confirmed by direct measurement of levels of FAs, in 84 
longitudinal analysis with a long followup, and in different populations. Nevertheless, no study 85 
measured FAsmore than once, and therefore it is not possible to examine the relationship between 86 
changes in levels of FAs and modifications of physical function. The main characteristics of 87 
observational studies are described in Table 1. 88 
POLYUNSATURATED FATTY ACID AND PHYSICAL FUNCTION: CLINICAL TRIALS 89 
Clinical trials in healthy older patients [12– 15,16&&,17&&,18&] and in older patients suffering 90 
from a chronic disease [19,20] have mostly demonstrated that n-3 PUFA improve muscle 91 
performance and physical function. Supplementation with 1.2 g/day of fish oil during 6-months in 92 
prefrail older women improved walking speed, but not hand grip or lower limb strength [14]. A recent 93 
study evaluated the effects of the supplementation of high doses n-3 PUFA (4 g/day) for 6 months, 94 
showing an improvement in muscle mass and performance in older adults [17&&]. In older women, 95 
fish oil supplementation increased resting metabolic rate, exercise-related energy expenditure, lean 96 
body mass and improved functional capacity [16&&]. On the contrary, some authors did not find any 97 
beneficial effects of n-3 PUFA on muscle mass, muscle strength and physical performance [15]. 98 
Positive results were also obtained in small clinical studies performed in older patients with different 99 
diseases. In patients suffering from chronic obstructive pulmonary disease, PUFA supplementation 100 
increased the effects of exercise training, in terms of peak exercise capacity and submaximal 101 
endurance time [19]. Few studies assessed the combined effect of exercise and n-3 PUFA. Overall, 102 
the effect of exercise training seems stronger than that of PUFA in increasing lean mass, muscle 103 
performance and physical capacity. Rodacki et al. [13] found that n-3 PUFA supplementation in 104 
combination with strength training significantly increased muscle strength and functional capacity 105 
gains compared with strength training alone in older women. However, n-3 supplementation alone 106 
before strength training did not have any effect [13]. At variance, resistance training increased muscle 107 
strength independent from the intake of PUFA, although an improvement in the skeletal muscle mass 108 
occurred only when it was combined with a healthy diet (with a n-6/n-3 ratio <2) [18&].As n-3 109 
PUFAs improvemuscle strength, it could be assumed that they also increase muscle mass. However, 110 
intervention studies provided conflicting results on this aspect [21&&]. A likely explanation of this 111 
inconsistency might be the short duration of many trials and, in some of them, the insufficient amount 112 
of n-3 PUFA used, as it appears that a minimum dose of 2 g/day is needed to stimulate muscle 113 
anabolism. Furthermore, the method used to measure muscle mass is relevant: dual radiograph 114 
absorptiometry and bioelectrical impedance analysis assess whole lean body mass, only half of which 115 
is represented by muscle and might therefore be unable to detect small changes in muscular mass. 116 
The main characteristics of intervention studies are described in Table 2. 117 
POLYUNSATURATED FATTY ACID AND PHYSICAL FUNCTION: BIOLOGICAL 118 
MECHANISMS 119 
The biological mechanisms by which PUFA improve muscular and physical function have been 120 
investigated but are not entirely clear yet. FAs have multiple functions at cellular level, being major 121 
components of membranes and being involved in several metabolic processes, by regulating the 122 
activity of enzymes and acting as signaling molecules. The available evidence suggests that n-3 123 
PUFAs are active at muscular level, in which they could increase the synthesis and decrease the 124 
breakdown of proteins [22]. PUFAs seem to counteract the blunted anabolic response to stimuli, for 125 
example protein intake and exercise, the so-called anabolic resistance, which contributes to the 126 
occurrence of sarcopenia in older patients. In a seminal article, Smith et al. demonstrated that PUFAs 127 
stimulate protein synthesis not in the basal state but during hyperaminoacidemia and 128 
hyperinsulinemia condition. This activity was associated with an increased activation of the 129 
mechanistic target of rapamycin (mTOR) pathway [23]. The same authors investigated whether n-3 130 
PUFA supplementation is able to increase the expression of genes involved in the regulation of 131 
mitochondrial function and anabolic pathways as well as decrease the expression of genes related to 132 
autophagy and atrophy of muscles [24&&]. They found that several genes involved in respiratory 133 
electron transport and oxidative phosphorylation, that is mitochondrial function, were increased. At 134 
the same time, pathways involved in calpain-mediated and ubiquitin-mediated proteolysis, mRNA 135 
translation and inhibition of mTOR signaling were significantly decreased by n-3 PUFA. Overall, the 136 
changes observed were modest, suggesting that n-3 PUFA may induce small changes in the muscle 137 
[24&&]. Interestingly, in animal models, n-3 PUFA have shown to reduce the rate of protein 138 
degradation, likely by means of the inhibition of the nuclear factor kappa B (NF-kB) pathway [22]. 139 
Other mechanisms have been proposed. When n-3 PUFAs are introduced, cell membranes of different 140 
tissues including the skeletal muscle incorporate them. This fact has been shown in human studies 141 
[25,26]. In addition, higher amounts of Ca2þ-ATPase and Naþ/Kþ-ATPase proteins might explain 142 
the increase in metabolic rate following n-3 PUFA ingestion [27]. n-3 PUFA may improve 143 
mitochondrial functions by modulating nuclear gene expression and the mitochondrial membrane. In 144 
the nucleus, n-3 PUFA might affect the expression of genes regulating the energy metabolism and 145 
mitochondrial function such as the peroxisome proliferator–activated receptor gamma coactivator 1-146 
alpha [28&]. In parallel, the activation of peroxisome proliferator–activated receptors (PPARs) may 147 
result in changes in energy metabolism by influencing mRNA, protein expression and the activity of 148 
various proteins. Furthermore, n-3 PUFA have been shown to increase the expression of genes 149 
involved in extracellular matrix organization, which are involved in the development and 150 
maintenance of the muscle [24&&]. The beneficial effect of PUFAs on the muscle and physical 151 
function could be explained in part by their anti-inflammatory properties [29]. First of all, they 152 
compete with n-6 PUFA, in particular arachidonic acid, as substrate for enzymes, such as 153 
cyclooxygenase and lipoxygenase that produce eicosanoids. Of note, the eicosanoids produced from 154 
n-3 PUFA are less powerful proinflammatory agents than those derived from arachidonic acid, and 155 
n-3 PUFAs are precursors of inflammation resolving molecules [29]. In this respect, it seems that the 156 
ratio of n-6 to n-3 PUFA in the diet might be important to reduce inflammation. Moreover, n-3 PUFA 157 
can decrease the synthesis of proinflammatory cytokines by binding to nuclear receptors. They 158 
prevent the degradation and subsequent translocation of the NF-kB complex to the nucleus in which 159 
it induces transcription of inflammatory cytokines. The reduction in NF-kB pathway activation is 160 
thought to be caused by an up-regulation in PPARg activity. In addition to direct action at the 161 
muscular tissue, n-3 PUFA could improve peripheral neuromuscular function, increasing muscle 162 
activation [30], nerve conduction velocity and the sensitivity to acetylcholine, which stimulates the 163 
contraction of the muscle [22]. 164 
DISCUSSION 165 
The majority of studies found beneficial effects of n-3 PUFA intake and supplementation on muscle 166 
mass, muscle strength and physical function in older patients. Several mechanisms are likely to 167 
explain the ability of n-3 PUFA to improve physical function. The most consistent effects of n-3 168 
PUFA supplementation is at the muscular level. First of all, they have a direct anabolic effect on the 169 
muscle that has been demonstrated also in older adults. n-3 PUFA might also reduce protein 170 
catabolism, although evidence in humans is limited. Mitochondrial function is enhanced by n-3 171 
PUFA, through different actions. A large body of research supports an important anti-inflammatory 172 
activity of n-3 PUFA, but its contribution to the positive effects on the muscle has still to be confirmed 173 
in humans. Up to now, the majority of clinical trials did not find changes in inflammatory markers, 174 
possibly because they included relatively healthy older patients, whose level of systemic 175 
inflammation was normal. Nevertheless, also in prefrail older women n-3 PUFA did not modify the 176 
levels of inflammatory markers [14]. Finally, an improvement of neuromuscular function might occur 177 
during supplementation. Although the positive effects of n-3 PUFA have been confirmed in different 178 
trials, there are several limitations in the available scientific evidence. First of all, the majority of 179 
trials included relatively healthy older patients or patients with a specific chronic disease. It would 180 
be extremely relevant to confirm the possibility to improve muscle function and physical performance 181 
also in older adults who are suffering from multimorbidity, frailty and sarcopenia as the current 182 
therapeutic strategies for this group are limited, that is exercise and nutritional interventions, which 183 
consist of protein and vitamin D supplementation [31,32&&]. Moreover, it would be important to 184 
explore the potential benefits of n-3 PUFA in older patients who experience an accelerated muscle 185 
and functional loss, for example due to periods of forced immobilization. Although the optimal dose 186 
of n-3 PUFA is not known, the majority of clinical trials investigated the effect of moderate or high 187 
dose supplements of long chain n-3 FAs, that is doses equal or above 1 g/day of EPA and DHA. 188 
These doses are higher than those currently recommended for healthy patients. As the intake of n-3 189 
PUFA is currently low in the majority of the population, the possibility to considerably increase the 190 
consumption of foods rich in long chain n-3 PUFA, that is fish, in particular fatty fish such as salmon, 191 
herring, halibut and mackerel, could be challenging. In this respect, supplementation might be the 192 
only effective strategy to achieve the desired intake. Another related but distinct issue is whether 193 
ALA, the precursor of long chain n-3 PUFA, might have similar effects on the muscle and on physical 194 
function. ALA, which is the most abundant n-3 FA in the Western diet, is present in vegetable oils 195 
and nuts, flax seeds and flaxseed oil, leafy vegetables and some animal fat. However, this question 196 
cannot be answered yet, as in the only study that evaluated a high dose of ALA supplement, the 197 
participants were also participating in a strength training program [18&]. Although available data 198 
suggest that the effect of exercise on the muscle and on physical function is greater than that of n-3 199 
PUFA, the combination of these two interventions has been tested in very few studies. All these 200 
points represent relevant topics that deserve further investigation. Finally, large-scale randomized 201 
controlled trials need to be performed to evaluate whether n-3 PUFA treatment can postpone the onset 202 
or slow the progression of physical function decline in older adults, using clinically relevant outcomes 203 
in this population, such as the prevention or recovery of mobility disability [33&]. 204 
CONCLUSION 205 
The available evidence suggests that n-3 PUFA might be a promising treatment to prevent and treat 206 
physical function impairment in older patients. However, large-scale clinical trials are needed to 207 
confirm this hypothesis. 208 
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